



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated:

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 18-09-2009 TO BE PUBLISHED 13-11-2009 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 99215488

**ENCL:**

## **NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

### **14-09-2009**

- |          |   |   |
|----------|---|---|
| 837/2009 | Siemens VAI Metals Technologies GmbH and Co.,<br>Austria<br>(Priority 28-6-2007 Austria)<br><b>DIVISIONAL</b> | “An apparatus for producing sponge iron from iron-oxide containing material in lump form” |
| 838/2009 | Sanofi-Aventis,<br>France<br>(Priority 16-09-2008 France)   | “Process for the preparation of 1,6,2,3-dianhydro-β-D-mannopyranose”                      |
| 839/2009 | Boehringer Ingelheim International GmbH.,<br>Germany<br>(Priority 16-09-2008 USA)                             | “Crystalline forms of a potent HCV inhibitor”   |
| 840/2009 | Rakan Khaled Y Alkhalaf,<br>Saudi Arabia<br>(Priority 16-04-2009 Europe)                                      | “Method to route a phone call”  |
| 841/2009 | H. Lundbeck A/C,<br>Denmark<br>(Priority 15-09-2008 Denmark)  | “Isoquinolinone derivatives as NK3 antagonists”   |

### **15-09-2009**

- |          |   |  |
|----------|---|--|
| 842/2009 | Nestec S.A.,<br>Switzerland<br>(Priority 24-09-2008 Europe)                       | “Acidified nutritional formula”                  |
| 843/2009 | Unilever PLC,<br>United Kingdom<br>(Priority 25-09-2008 India)                    | “Water purification composition and method”      |
| 844/2009 | Boehringer Ingelheim International GmbH.,<br>Germany<br>(Priority 17-09-2008 USA) | “Combination therapy for treating HCV infection” |

845/2009	Methanol Casale S.A., Switzerland (Priority 23-09-2008 Europe)	“Heat exchanger with radially arranged elements for isothermal chemical reactors”
846/2009	BDI-Biodiesel International AG, Austria (Priority 17-09-2008 Europe)	“Process for obtaining combustibles and fuels, respectively”
847/2009	Novartis AG, Switzerland (Priority 17-09-2008 USA)	“Salts of N-[6-(CIS-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy)[1,1’-biphenyl]-3-carboxamide”
848/2009	Novartis AG, Switzerland (Priority 17-09-2008 USA)	“Organic compounds and their uses”
849/2009	Takeda Pharmaceutical Company Limited, Japan (Priority 16-09-2008 Japan)	“Film-coated scored tablet”
850/2009	Agriculture Victoria Services Pty Limited, Australia Molecular Plant Breeding Nominees Limited Australia (Priority 15-09-2008 USA)	“Plant technology”
<b><u>16-09-2009</u></b>		
851/2009	Takeda Pharmaceutical Company Limited, Japan (Priority 25-09-2008 USA)	“Solid pharmaceutical composition”
852/2009	Abbott Laboratories, USA (Priority 16-09-2008 USA)	“Novel compounds as cannabinoid receptor ligands”
853/2009	Sicpa Holding SA., Switzerland (Priority 03-10-2008 PCT)	“Paired optically variable security element”

**17-09-2009**

- |          |   |   |
|----------|---|---|
| 854/2009 | CJ Cheiljedang Corporation,<br>Korea<br>(Priority 24-12-2008 Korea)                   | “Novel bacteriophage and antibacterial compositions comprising the same”      |
| 855/2009 | Ortho-McNeil-Janssen<br>Pharmaceuticals, Inc.,<br>USA<br>(Priority 18-09-2008 Europe) | “Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside” |
| 856/2009 | Ghulam Abid Chaudhary,<br>Lahore,<br>Pakistan   | “Synthetic tea substitute & process for manufacture thereof”                  |

**18-09-2009**

- |          |   |   |
|----------|---|---|
| 857/2009 | Schering Corporation,<br>USA<br>(Priority 24-09-2008 USA) | “Compounds for the treatment of inflammatory disorders” |
| 858/2009 | Schering Corporation,<br>USA<br>(Priority 24-09-2008 USA) | “Compounds for the treatment of inflammatory disorders” |
| 859/2009 | Novartis AG,<br>Switzerland<br>(Priority 24-09-2008 USA)  | “Galenic formulations of organic compounds”             |
| 860/2009 | Novartis AG,<br>Switzerland<br>(Priority 22-09-2008 USA)  | “Galenic formulations of organic compounds”             |
| 861/2009 | Basf SE.,<br>Germany<br>(Priority 24-09-2008 USA)         | “Pyrazole compounds for controlling invertebrate pests” |

**APPLICATION ACCEPTED**

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

246/2000	SmithKline Beecham Biologicals S.A., Belgium	“An immunogenic composition comprising a pneumococcal polysaccharide antigen and a protein antigen”
----------	--	---

A61K37/005

**140282**



The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from streptococcus pneumoniae, and optionally a Th 1-inducing adjuvant.

245/2003	Boehringer ingelheim Pharmaceuticals, Inc., USA	“Glucocorticoid compound”
----------	---	---------------------------

CO7D 295/04

**140283**

Compound of Formula (1A) and Formula (1B)



wherein  $R^1, R^2, R^3, R^4, R^5$ , and  $R^6$  are as defined herein for formula (1A) or Formula (1B), pharmaceutical composition containing such compound and method of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using the these compounds.

444/2005 Alia B. Munshi,  
S. Abdul Ali,  
Askari Begum,  
Sadiqa Shakir,  
P.C.S.I.R., Karachi,  
Pakistan

“A process for the production of biscuit in a compact form as dietary supplement in emergency”

A21D 17/00

**140284**

The present invention related to a process for the production of 40 kg whole some ready to consume, tasty, ultra high calorie Emergency Ration for our Defense Forces and for the paramilitary staff to meet unforeseen situation by processing 2.4kg of 16 mesh farina and 10 mesh size of 12 kg papa crisp, 6 kg sugar and 2.4kg roasted gram, mixing in an electric mixer with 4.8 kg milk powder, adding 2.4 kg corn and wheat flour, mixing thoroughly, subsequently supplementing the mixture with 6 kg butter fat containing 2.4 g of TBHQ and 320 g of gum with 1.2 kg deoiled coconut powder, again mixing gently, thereafter maintaining temperature of the mixture at  $100 + 2^{\circ}\text{C}$  with occasional stirring till light brown in colour and attaining 2 - 3% moisture level,

simultaneously preparing vitamins and mineral mixture, comprising of 103.0 mg vitamin-A, palmitat, 0.1 g riboflavin, 0.11 g thiamin hydrochloride, 0.96 g niacin, 5.15 g vitamin - C, 5.15 g 520g tribasic calcium phosphate and 20.0g Ca propionate respectively, mixing one by one and adding to the previously prepared light brown mixture to get final product of wholesome Emergency Ration, finally pressing the food in the form of biscuits in such a way that nine biscuits weighing 250g may provide one day restricted energy 1250 K.calolries, 15g protein, requirement of a soldier, with other essential nutrients for unforeseen tactical situations.

337/2007 GlaxoSmithKline  
Biologicals s.a,  
Belgium  
The Brigham and Women's  
Hospital, Inc.,  
USA

“A process for conjugation of PNAG to a carrier protein”

A61K 47/48, A61K 39/385, A61P 31/04

**140285**

The present application describes a process for conjugating a PNAG poly-N-acetyted glucosarine which is less than 40% N-acetylated to a carrier protein comprising the steps of a) activating the PNAG by adding a linker comprising a maleimide group to form an activated PNAG b) activating the carrier protein by adding a linker comprising a sulphhydryl group to form an activated carrier protein and c) reacting the activated PNAG and the activated carrier protein to form a PNAG-carrier protein conjugate.

339/2007 Otsuka Pharmaceutical  
Factory, Inc.,  
Japan

“Multi-chamber container comprising a medicine accommodation chamber”


B65D 81/32, A61J 1/05, B65D 33/36, B65D 81/24,

**140286**

It is an object of the resent invention to provide a multi-chamber container that has a weak seal portion having an increased joining strength and being easy to be opened when in

administration of medicine, and that is provided at low cost. The multi-chamber container includes a medicine accommodation chamber 1, a diluting solution chamber 3 jointed to one side of the medicine accommodation chamber 1 via a partitioning weak seal portion 2, an unoccupied chamber 5 having a port 6 and jointed to an opposite side of the medicine accommodation chamber 1 via a discharging weak seal portion 4, a film member 7 attached to the medicine accommodation chamber 1 for increasing a joining strength of each of the discharging weak seal portion 2 and the discharging weak seal portion 4, the discharging weak seal portion 4 having an easy-to-open portion 8 that enables the discharging weak seal portion 4 to easily be opened therethrough.

**FIG. 1**




956/2008 Dystar Textilfarben GmbH & Co. Deutschland KG., Germany

“Disperse azo dye”  
C09B 61/00, C09B 29/06

**140287**

The present invention provides a dye of the general formula (1)



where D, R<sup>1</sup> to R<sup>6</sup>, X, m and n are each as defined as

D is the residue of a diazo component;

R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, hydroxyl, halogen, -NHCHO, -NHCO(C<sub>1</sub>-C<sub>6</sub>)-alkyl or -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R<sup>2</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy or halogen;

R<sup>3</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, substituted (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>4</sub>)-alkenyl or substituted (C<sub>3</sub>-C<sub>4</sub>)-alkenyl

or R<sup>2</sup> and R<sup>3</sup> combine to form the radical - C<sup>+</sup>H(CH<sub>3</sub>)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, where the carbon atom marked \* is attached to the phenyl nucleus;

R<sup>4</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R<sup>5</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R<sup>6</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

X is phenyl, thiophenyl, sulfonylphenyl or phenoxy;

n is 0, 1, or 2; and

m is 0 or 1.

### SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

140015	Janssen Pharmaceutica N.V., Belgium	209/1999
140016	AstraZeneca AB, Sweden	709/2000
140017	Wyeth, USA	820/2000
140018	Wyeth, USA	1072/2000
140019	Wyeth, USA	237/2001
140020	F. Hoffmann-La Roche AG, Switzerland	405/2002
140021	AstraZeneca AB, Sweden	1090/2002
140022	Wyeth, USA	359/2003
140023	Boehringer Ingelheim Pharma GmbH & Co. KG. Germany	714/2003
140024	F. Hoffmann-La Roche AG, Switzerland	835/2003
140025	Basf Aktiengesellschaft, Germany	773/2004
140026	Wyeth, USA	800/2004
140027	Pfizer Products Inc. USA	881/2004
140028	Pfizer Inc. USA	1052/2004

140029	Unilever PLC, England	1063/2004
140030	Lurgi Zimmer GmbH Germany	67/2005
140031	PUMA Aktiengesellschaft Rudolf Dassler Sport, Germany	581/2005
140032	Theravance, Inc. USA	301/2006
140033	Wyeth, USA	894/2006
140034	Wyeth, USA	964/2006
140035	Wyeth, USA	978/2006
140036	Wyeth, USA	1067/2006
140037	AstraZeneca AB, Sweden	1092/2006
140038	Janssen Pharmaceutica N.V. Belgium	1179/2006
140039	Pfizer Inc. USA	489/2007
140040	Sanofi-Aventis France	1416/2007

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 99215488